Our Pipeline

Deep Clinical and Preclinical Pipeline
F-star’s clinically validated multispecific antibody platform has delivered a deep proprietary and partnered pipeline of promising clinical and preclinical drug product candidates.
FS118: First-in-class LAG-3/PD-L1 mAb2 bispecific antibody

Our most advanced clinical program, FS118, targeting LAG-3 and PD-L1, is currently in a phase 2 Proof of Concept study in acquired resistance head and neck cancer, as well as in a Phase 2 trial in checkpoint naïve non-small cell lung cancer (NSCLC) and diffuse large B cell lymphoma (DLBCL) patients.

FS118 »
FS120: First-in-class OX40/CD137 mAb² dual agonist bispecific antibody

FS120 is our dual conditional agonist targeting OX40 and CD137 with the goal of improving outcomes with current standard of care treatments, and is currently in Phase 1 trials.

FS120 »
FS222: Potentially best-in-class CD137/PD-L1 mAb² bispecific antibody

FS222 is designed to both stimulate CD137 and inhibit PD-L1, and is in Phase 1 trials currently. We believe FS222 has applicability in PD-L1 low tumors which remains an area with significant unmet need.

FS222 »
SB 11285: Second generation STING agonist for intravenous administration

SB 11285 is our second generation STING agonist, currently in a Phase 1 study as both monotherapy and in combination with atezolizumab.

SB 11285 »